Stoke Therapeutics (STOK) Short Interest Ratio & Short Volume $11.86 -0.18 (-1.50%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$11.86 0.00 (0.00%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Stoke Therapeutics Short Interest DataStoke Therapeutics (STOK) has a short interest of 11.53 million shares, representing 23.34% of the float (the number of shares available for trading by the public). This marks a -4.79% decrease in short interest from the previous month. The short interest ratio (days to cover) is 16.7, indicating that it would take 16.7 days of the average trading volume of 675,368 shares to cover all short positions.Current Short Interest11,530,000 sharesPrevious Short Interest12,110,000 sharesChange Vs. Previous Month-4.79%Dollar Volume Sold Short$130.87 millionShort Interest Ratio16.7 Days to CoverLast Record DateJune 30, 2025Outstanding Shares54,597,000 sharesShort Percent of Float23.34%Today's Trading Volume545,119 sharesAverage Trading Volume675,368 sharesToday's Volume Vs. Average81% Short Selling Stoke Therapeutics? Sign up to receive the latest short interest report for Stoke Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSTOK Short Interest Over TimeSTOK Days to Cover Over TimeSTOK Percentage of Float Shorted Over Time Stoke Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/202511,530,000 shares $130.87 million -4.8%23.3%16.7 $11.35 6/15/202512,110,000 shares $139.63 million +0.7%24.5%16 $11.53 5/31/202512,030,000 shares $115.61 million +3.1%25.6%14.7 $9.61 5/15/202511,670,000 shares $112.38 million -9.1%24.8%14.1 $9.63 4/30/202512,840,000 shares $125.32 million +2.2%N/A14.9 $9.76 4/15/202512,560,000 shares $97.34 million +3.9%26.7%14.5 $7.75 3/31/202512,090,000 shares $80.40 million +3.3%25.7%13.5 $6.65 3/15/202511,710,000 shares $100.71 million +4.8%24.9%13.9 $8.60 2/28/202511,170,000 shares $87.68 million +10.7%23.8%14.1 $7.85 2/15/202510,090,000 shares $107.76 million +12.2%21.5%12.9 $10.68 Get the Latest News and Ratings for STOK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20258,990,000 shares $103.21 million +2.7%N/A12.4 $11.48 1/15/20258,750,000 shares $83.04 million +17.0%N/A13.5 $9.49 12/31/20247,480,000 shares $82.50 million +3.0%N/A12.1 $11.03 12/15/20247,260,000 shares $87.56 million +7.9%N/A12.3 $12.06 11/30/20246,730,000 shares $81.50 million +5.2%N/A11.1 $12.11 11/15/20246,400,000 shares $76.99 million -4.5%N/A11.6 $12.03 10/31/20246,700,000 shares $82.81 million -1.3%N/A12.7 $12.36 10/15/20246,790,000 shares $86.17 million -2.7%N/A12.7 $12.69 9/30/20246,980,000 shares $85.78 million -19.9%N/A12.7 $12.29 9/15/20248,710,000 shares $126.03 million -5.8%N/A14.4 $14.47 8/31/20249,250,000 shares $134.59 million -6.5%N/A15.4 $14.55 8/15/20249,890,000 shares $140.93 million +0.7%N/A15.2 $14.25 7/31/20249,820,000 shares $147.01 million -4.7%N/A13.6 $14.97 7/15/202410,300,000 shares $150.17 million +8.8%N/A13 $14.58 6/30/20249,470,000 shares $127.94 million +13.3%N/A11 $13.51 6/15/20248,360,000 shares $135.85 million +1.7%N/A5.5 $16.25 5/31/20248,220,000 shares $120.18 million +3.9%N/A5.7 $14.62 5/15/20247,910,000 shares $111.77 million -4.8%N/A5.8 $14.13 4/30/20248,310,000 shares $91.66 million +50.3%N/A6.6 $11.03 4/15/20245,530,000 shares $67.52 million +11.7%N/A4.8 $12.21 3/31/20244,950,000 shares $66.83 million +39.4%15.0%4.9 $13.50 3/15/20243,550,000 shares $22.68 million -5.6%12.8%6.3 $6.39 2/29/20243,760,000 shares $29.10 million -5.3%13.5%16.7 $7.74 2/15/20243,970,000 shares $21.08 million -3.9%14.3%18.2 $5.31 1/31/20244,130,000 shares $19.99 million +20.1%14.8%20.6 $4.84 1/15/20243,440,000 shares $17.61 million +3.6%12.4%16.4 $5.12 12/31/20233,320,000 shares $17.46 million +4.1%11.9%14.7 $5.26 12/15/20233,190,000 shares $16.33 million -20.7%11.5%14 $5.12 11/30/20234,020,000 shares $15.24 million -1.5%14.5%18.6 $3.79 11/15/20234,080,000 shares $18.81 million -5.3%14.7%21 $4.61Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 10/31/20234,310,000 shares $16.42 million -4.7%15.9%19.1 $3.81 10/15/20234,520,000 shares $18.51 million -1.7%16.7%11.3 $4.10 9/30/20234,600,000 shares $18.12 million -3.6%17.0%11.3 $3.94 9/15/20234,770,000 shares $23.75 million +3.0%16.5%11.9 $4.98 8/31/20234,630,000 shares $26.02 million +3.8%16.0%10.7 $5.62 8/15/20234,460,000 shares $24.84 million -18.9%15.4%10.1 $5.57 7/31/20235,500,000 shares $36.52 million -3.7%19.1%13.3 $6.64 7/15/20235,710,000 shares $57.96 million -0.2%19.9%17.4 $10.15 6/30/20235,720,000 shares $60.80 million +4.8%19.9%23.5 $10.63 6/15/20235,460,000 shares $70.60 million +4.4%19.0%21.2 $12.93 5/31/20235,230,000 shares $58.58 million +7.2%18.2%23.3 $11.20 5/15/20234,880,000 shares $57.29 million +3.6%17.0%20.8 $11.74 4/30/20234,710,000 shares $41.87 million +20.8%16.4%20.2 $8.89 4/15/20233,900,000 shares $31.86 million -8.7%13.6%13.4 $8.17 3/31/20234,270,000 shares $35.57 million +8.4%15.9%14.7 $8.33 3/15/20233,940,000 shares $36.05 million +1.3%14.7%12 $9.15 2/28/20233,890,000 shares $34.58 million No Change14.5%11.9 $8.89 2/15/20233,890,000 shares $35.05 million +1.8%16.3%12.1 $9.01 1/31/20233,820,000 shares $38.05 million -1.0%16.0%9.5 $9.96 1/15/20233,860,000 shares $37.64 million +0.5%16.2%11.4 $9.75 12/30/20223,840,000 shares $35.44 million +6.7%16.1%10.8 $9.23 12/15/20223,600,000 shares $29.88 million -1.6%15.1%11.1 $8.30 11/30/20223,660,000 shares $27.60 million -13.3%16.7%11.2 $7.54 11/15/20224,220,000 shares $42.16 million -8.1%19.2%13.3 $9.99 10/31/20224,590,000 shares $68.16 million -10.9%21.1%19.5 $14.85 10/15/20225,150,000 shares $61.34 million -5.5%23.7%22.5 $11.91 9/30/20225,450,000 shares $69.98 million +3.6%25.0%25 $12.84 9/15/20225,260,000 shares $86.74 million -1.5%24.2%24.5 $16.49 8/31/20225,340,000 shares $80.42 million +1.9%27.0%23.5 $15.06 8/15/20225,240,000 shares $112.40 million -3.3%26.5%21.2 $21.45 7/31/20225,420,000 shares $80.16 million -7.2%27.6%18.5 $14.79 7/15/20225,840,000 shares $88.18 million -3.2%29.7%20 $15.10 6/30/20226,030,000 shares $79.66 million +1.9%30.7%20.8 $13.21 6/15/20225,920,000 shares $63.40 million +0.5%30.1%18 $10.71 5/31/20225,890,000 shares $71.33 million +1.9%30.0%18.4 $12.11 5/15/20225,780,000 shares $86.06 million -6.3%29.4%18.3 $14.89 4/30/20226,170,000 shares $89.09 million -0.2%34.6%19.7 $14.44 4/15/20226,180,000 shares $125.70 million +6.4%34.7%18.2 $20.34 3/31/20225,810,000 shares $122.30 million +8.6%33.0%16.3 $21.05 3/15/20225,350,000 shares $108.82 million +25.3%30.4%16.7 $20.34 2/28/20224,270,000 shares $83.27 million +17.0%24.6%14.3 $19.50 2/15/20223,650,000 shares $70.70 million +0.3%21.0%12.3 $19.37 1/31/20223,640,000 shares $68.98 million +17.4%20.2%13.5 $18.95 1/15/20223,100,000 shares $60.70 million +12.7%15.6%12.5 $19.58 12/31/20212,750,000 shares $65.97 million +1.9%N/A14.1 $23.99 12/15/20212,700,000 shares $54.41 million +10.7%13.6%14.7 $20.15 11/30/20212,440,000 shares $60.76 million -0.8%12.3%14.6 $24.90 11/15/20212,460,000 shares $70.33 million +21.8%12.4%17.3 $28.59 10/29/20212,020,000 shares $46.12 million +7.5%10.2%17.4 $22.83 10/15/20211,880,000 shares $44.22 million -5.1%9.5%16.1 $23.52Trump’s treachery (Ad)Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.Millions of Americans are about to be wiped out, while others could make a fortune… click here to ma 9/30/20211,980,000 shares $50.37 million +28.6%10.0%16.4 $25.44 9/15/20211,540,000 shares $37.13 million -0.7%7.8%11.1 $24.11 8/31/20211,550,000 shares $40.58 million +6.2%7.8%11.8 $26.18 8/13/20211,460,000 shares $37.57 million +5.0%7.4%9.8 $25.73 7/30/20211,390,000 shares $39.80 million -32.2%7.0%8.8 $28.63 7/15/20212,050,000 shares $67.67 million -12.0%10.4%12.1 $33.01 6/30/20212,330,000 shares $78.43 million -4.1%N/A12.2 $33.66 6/15/20212,430,000 shares $89.13 million -10.3%12.8%13 $36.68 5/28/20212,710,000 shares $107.48 million -11.7%14.3%14 $39.66 5/14/20213,070,000 shares $102.48 million +2.7%16.2%15.8 $33.38 4/30/20212,990,000 shares $100.73 million -5.1%15.8%15.3 $33.69 4/15/20213,150,000 shares $108.08 million -0.3%16.7%17.1 $34.31 3/31/20213,160,000 shares $117.08 million +10.5%16.8%19.8 $37.05 3/15/20212,860,000 shares $146.60 million -13.3%15.2%17.3 $51.26 2/26/20213,300,000 shares $193.18 million -2.1%17.5%21.9 $58.54 2/12/20213,370,000 shares $207.76 million -3.2%17.9%21.1 $61.65 1/29/20213,480,000 shares $215.79 million +0.9%18.8%21.4 $62.01 1/15/20213,450,000 shares $225.35 million -2.8%18.6%21.6 $65.32 12/31/20203,550,000 shares $213.25 million +19.5%19.5%23.8 $60.07 12/15/20202,970,000 shares $166.44 million +0.7%16.3%21.8 $56.04 11/30/20202,950,000 shares $150.95 million +3.9%16.2%24.5 $51.17 11/15/20202,840,000 shares $127.77 million -0.7%16.5%24.9 $44.99 10/30/20202,860,000 shares $113.86 million -1.0%18.1%33.1 $39.81 10/15/20202,890,000 shares $111.53 million +1.8%18.3%33.1 $38.59 9/30/20202,840,000 shares $95.11 million +1.4%18.0%27.3 $33.49 9/15/20202,800,000 shares $91.59 million +1.1%17.7%23.6 $32.71 8/31/20202,770,000 shares $81.35 million +3.4%17.5%21.5 $29.37 8/14/20202,680,000 shares $77.72 million +3.9%17.0%20 $29.00 7/31/20202,580,000 shares $64.99 million +3.2%16.5%18.5 $25.19 7/15/20202,500,000 shares $58.13 million -29.6%16.0%18.5 $23.25 STOK Short Interest - Frequently Asked Questions What is Stoke Therapeutics' current short interest? Short interest is the volume of Stoke Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, traders have sold 11,530,000 shares of STOK short. 23.34% of Stoke Therapeutics' shares are currently sold short. Learn More on Stoke Therapeutics' current short interest. What is a good short interest ratio for Stoke Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. STOK shares currently have a short interest ratio of 17.0. Learn More on Stoke Therapeutics's short interest ratio. Which institutional investors are shorting Stoke Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Stoke Therapeutics: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Stoke Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.34% of Stoke Therapeutics' floating shares are currently sold short. Is Stoke Therapeutics' short interest increasing or decreasing? Stoke Therapeutics saw a decrease in short interest during the month of June. As of June 30th, there was short interest totaling 11,530,000 shares, a decrease of 4.8% from the previous total of 12,110,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Stoke Therapeutics' short interest compare to its competitors? 23.34% of Stoke Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Stoke Therapeutics: Mirum Pharmaceuticals, Inc. (15.35%), ImmunityBio, Inc. (37.57%), Arrowhead Pharmaceuticals, Inc. (9.55%), Apellis Pharmaceuticals, Inc. (22.25%), Twist Bioscience Corporation (0.05%), NewAmsterdam Pharma Company N.V. (11.06%), Apogee Therapeutics Inc. (23.20%), Recursion Pharmaceuticals, Inc. (35.52%), Denali Therapeutics Inc. (9.91%), Vericel Corporation (4.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Stoke Therapeutics stock? Short selling STOK is an investing strategy that aims to generate trading profit from Stoke Therapeutics as its price is falling. STOK shares are trading down $0.18 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Stoke Therapeutics? A short squeeze for Stoke Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of STOK, which in turn drives the price of the stock up even further. How often is Stoke Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including STOK, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Mirum Pharmaceuticals Short Interest ImmunityBio Short Interest Arrowhead Pharmaceuticals Short Interest Apellis Pharmaceuticals Short Interest Twist Bioscience Short Interest NewAmsterdam Pharma Short Interest Apogee Therapeutics Short Interest Recursion Pharmaceuticals Short Interest Denali Therapeutics Short Interest Vericel Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:STOK) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stoke Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
